This virtual series was created in collaboration with the MidAtlantic AETC Ending the HIV Epidemic (EHE) Workgroup. This comprehensive webinar series aims to provide healthcare professionals with the latest strategies and tools to end the HIV epidemic. Each training session will focus on one of the four key strategies that make up the Ending the HIV Epidemic U.S. Initiative, which include: diagnosing all individuals with HIV as early as possible, treating HIV rapidly and effectively to achieve sustained viral suppression, preventing new HIV transmissions using proven interventions like PrEP, and responding quickly to potential HIV outbreaks to get needed prevention and treatment services to those who need them.
For more information on this series, visit: https://www.maaetc.org/p/ehemaaetc
DESCRIPTION:
This program will review key elements of the key strategy: Prevent
Speaker:
Ingrid McDowell, DrPH(c),MPH
Administrator III
Center for Harm Reduction Services
Prevention & Promotion Division (formerly SAPI)
Behavioral Health Administration
Objectives
Upon completion of this course, participants will be able to:
- Identify strategies to reduce HIV transmission in persons with substance use disorder
- Discuss the clinical management of HIV PrEP for people who use substances.
- Describe how stigma and substance use disorders (SUDs) influence various aspects of HIV prevention and screening.
- Review services and resources for persons with SUDs that can improve PrEP uptake, support HIV prevention, and enhance overall well-being.
Acknowledgement:
The MidAtlantic AIDS Education and Training Center (MAAETC) is supported by DHHS, Health Resources and Services Administration (HRSA) as part of a cooperative agreement of $3,561,880 and 0% financed with non-governmental sources. The program aims to provide HIV training and technical assistance to USPHS Region 3 (Pennsylvania, Maryland, Delaware, the District of Columbia, Virginia, and West Virginia).
The contents in this presentation are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government. For more information, please visit HRSA.gov.
Disclaimer:
Funding for this presentation was made possible in part by TR7HA53201-01-00 from the Health Resources and Services Administration HIV/AIDS Bureau. The views expressed do not necessarily reflect the official policies of the Department of Health and Human Services nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government. Any trade/brand names for products mentioned during this presentation are for training and identification purposes only.
